ArticleFrontiers in medicine2025
Prognostic value and immune infiltration of anoikis-related genes in osteosarcoma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there is no research on building osteosarcoma (OS) prognostic models based on single-cell RNA sequencing (scRNA-seq) and anoikis-related genes (ARGs). Methods: Differential genes between osteoblasts cells and osteosarcoma cells were identified using scRNA-seq, and ARGs were determined by Genecard database. Lasso regression was employed to investigate hub genes and construct the model based on TARGET. Kaplan-Meier survival analysis was applied to compare the survival differences. ROC curves were used to evaluate the predictive performance of the model. CIBERSORT and ESTIMATE algorithms were conducted to calculate immune cell infiltration abundance. Finally, qRT-PCR and immunohistochemistry experiments were conducted to validate the results. Results: A predictive model containing four modeling genes (MYC, BNIP3, IGFBP5, and SPP1) was successfully constructed, with AUC values of 0.836, 0.837, and 0.836 for 1-, 3-, and 5-year patient prognosis, respectively. Importantly, the model also showed good predictive value in two validation set. The infiltration of immune cells in different risk groups showed significant differences. The modeling genes were associated with the expression of various immune checkpoints and the response to immune therapy. qRT-PCR showed MYC, BNIP3, IGFBP5, and SPP1 substantially exhibited a trend of high expression in osteosarcoma cells. Immunohistochemistry suggested that in osteosarcoma patients with poorer prognosis, the expression of these four hub genes was significantly elevated. Conclusions: We have developed an effective model for predicting osteosarcoma prognosis and immune response, which may provide valuable insights for osteosarcoma prognostic evaluation and immune therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.